research Growth inhibition of mouse skin tumor by serine protease inhibitor ONO-3403.
ONO-3403 effectively reduces mouse skin tumor growth without side effects.
Search
for
Sort by
Research
360-390 / 1000+ results
research Refractory/relapse thrombocytopenia in a patient with Evans' syndrome successfully treated with zanubrutinib
A girl with Evans' syndrome had her low platelet count successfully treated with zanubrutinib.
research Pityriasis rubra pilaris unveiling a case of a new onset hepatitis C infection
A woman with a skin disorder was found to have hepatitis C, which may be linked, and was safely treated with methotrexate.
research Interventions for chronic pruritus of unknown origin
Serlopitant may help reduce itch, but more research is needed.
research Upadacitinib for management of alopecia areata and rheumatoid arthritis: Letter to the editor
Upadacitinib significantly improved both rheumatoid arthritis and alopecia areata in a patient.
research Isozyme phenotypes of polyoma virus tumors in mice.
DNA virus-induced tumors have consistent isozyme profiles, unlike other tumor types.
research Pre-clinical non-viral vectors exploited forin vivoCRISPR/Cas9 gene editing: an overview
Non-viral vectors show promise for safe and effective CRISPR/Cas9 gene editing in treating diseases.
research P‐30 Use of fipronil for treatment of Lynxacarus radovskyi in outdoor cats in Rio de Janeiro (Brazil)
Fipronil effectively treats Lynxacarus radovskyi in outdoor cats.
research Astilbin Activates the Reactive Oxidative Species/PPARγ Pathway to Suppress Effector CD4+ T Cell Activities via Direct Binding With Cytochrome P450 1B1
Astilbin can potentially calm overactive immune responses, like in Type 1 Diabetes, by suppressing certain cell activities and reducing inflammation.
research Pulse cyclophospamide in severe lupus nephritis: Southern Indian experience
IV cyclophosphamide effectively treated severe lupus nephritis in Indian patients, but longer follow-up is needed.
research 575 INTASYL self-delivering RNAi: A flexible platform to treat dermatological malignancies
INTASYL is a promising, adaptable RNAi technology for treating skin cancers.
research Finasteride, A Steroid 5α-Reductase Inhibitor, Does Not Affect the Oxidative Metabolism of Antipyrine
Finasteride doesn't affect antipyrine metabolism, so interactions with cytochrome P-450 enzyme drugs are unlikely.
research Other Products Being Developed by Pharmaceutical and Cosmetic Companies
Minoxidil can cause hair growth as a side effect.
research Repurposing Finasteride as a quorum sensing inhibitor in Pseudomonas aeruginosa
Finasteride may help treat Pseudomonas aeruginosa infections by reducing its harmful activities.
research Low-dose naltrexone: a novel adjunctive treatment in symptomatic alopecias?
Low-dose naltrexone might be a cheap and effective additional treatment for hair loss with scalp discomfort due to its anti-inflammatory effects and few side effects.
research PO.8.170 Drug-induced lupus or systemic lupus erythematosus after experimental COVID-19 therapy: difficulties in differential diagnosis
Distinguishing drug-induced lupus from systemic lupus is challenging and requires careful monitoring.
research Repurposing Auranofin for Oncology and Beyond: A Brief Overview of Clinical Trials as Mono- and Combination Therapy
Auranofin shows promise as a cancer treatment, especially when combined with other therapies.
research Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in patients with alopecia areata: efficacy and safety results of a phase II, multicenter, randomized, double-blinded, placebo-controlled trial
Deucravacitinib did not significantly improve hair regrowth in alopecia areata patients.
research Remote loading of minoxidil in nano-reservoirs leads to polymorphism and controlled release
research Isolation and validation of antimalarial compounds from Phyllanthus emblica leaves for new antimalarial drug development
Phyllanthus emblica leaves show potential for developing new antimalarial drugs with low toxicity.
research UNITY INOVA NMR Spectrometer Systems Installation Planning
Divalproex sodium significantly improved headaches in two-thirds of patients.
research Combined drug triads for synergic neuroprotection in retinal degeneration
Using three different drugs together may better treat eye diseases like glaucoma and macular degeneration.
research Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI)
BI 2536 had limited effectiveness against several advanced cancers and caused significant side effects.
research Designed, Synthesis, In Vitro and Computational Analyses of Anticancer Nicotinamide Derivatives
Compound N4 effectively kills breast cancer cells and compounds N2 and N3 have strong antibacterial and antifungal properties.
research Effective treatment with afoxolaner (NexGard) of Trixacarus caviae in a pet guinea pig
Afoxolaner effectively treats mange in guinea pigs with one dose.
research 218 Chemokine receptor CCR5 is the novel target for the treatment of alopecia areata
Blocking the CCR5 receptor may be a new way to treat hair loss from alopecia areata.
research Drug-induced postinfantile giant cell hepatitis
Certain liver diseases respond well to specific treatments and have varying risks for liver cancer.
research New Nonsteroidal Molecules as Blockers of the Steroidogenic Pathway
New nonsteroidal molecules can potentially increase dihydrotestosterone in neurons by blocking certain enzymes, without affecting prostate and seminal vesicle weight.
research ANALYSIS OF THE BACKGROUND LEVEL OF CYTOKINES M1 AND M2 OF THE MACROPHAGE PHENOTYPE IN PATIENTS WITH REVISION RHINOPLASTY AFTER THE USE OF THE DRUG PDRN
PDRN may reduce inflammation and complications in revision rhinoplasty for patients with high fibrinogen levels.
research 267 Single- and multiple-ascending dose studies of DS-2325a, a KLK5 inhibitor for the treatment of Netherton syndrome
DS-2325a is safe and well-tolerated, supporting further development for Netherton Syndrome treatment.